Medichem Research, Inc.

Lemont, IL 60439

SBIR Award Summary

Total Number of Awards 20
Total Value of Awards $762K
First Award Date 08/15/93
Most Recent Award Date 09/01/01

Key Personnel

Last Name Name Awards Contact
Lin Yuh-Meei Lin 2
Xu Ze-Qi Xu 5
Boulanger William Boulanger 1
Zembower David E Zembower 7
Flavin Michael T Flavin 2
Zhou Li-Ming Zhou 1
Huang Jinkun Huang 1
Mathews Jude E Mathews 1

20 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/01 - 12/31/02

DESCRIPTION (provided by applicant): We propose to design, synthesize and evaluate novel CPTs for the treatment of cancer. Extensive investigations on CPTs, specific topoisomerase I inhibitors, have led to the FDA approval of two water-soluble derivatives of CPT. However, under physiological conditions, the intrins...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/01 - 02/28/02

DESCRIPTION (provided by applicant): The usefulness of arylboronic acids or esters in organic synthesis, biology and molecular recognition leads to the origin of this proposal. Classical preparations of arylboronic acids use harsh conditions that can only be tolerated by a very limited number of functional groups....

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/06/01 - 10/31/01
PI: Ze-Qi Xu

DESCRIPTION (Adapted from the application):Through the TAACF screening program sponsored by NIAID, a naturally occurring pyranocoumarin compounds were identified to be active against Mycobacterium tuberculosis. Further evaluation of the leading compound, (+)-calanolide A. demonstrated that it was active against...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/00 - 09/30/00
PI: Ze-Qi Xu

Through the TAACF screening program sponsored by NIAID, naturally occurring anti-HIV agent (+)-Calanolide A was found to be active against Mycobacterium tuberculosis. It is the first compound identified to possess anti-mycobacterial and antiretroviral activities against both HIV and TB. Therefore, (+)-Calanolide A may be a powerful agent to trea...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/00 - 02/28/01

DESCRIPTION (Adapted from the application): The goal of this Phase II project is the synthesis and evaluation of indolocarbazole analogues as poisons of human topoisomerase I (Topo I), an enzyme which represents an attractive target for development of antitumor agents. The Phase I study involved synthesis of all four "symmetrical" regioisomers o...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/99 - 12/31/99

Treatment of AIDS is currently limited to inhibitors of the human immunodeficiency virus (HIV) enzymes protease and reverse transcriptase. Integrase plays a critical role in the life cycle of HIV, and is a prime target for a new class of inhibitors. One very attractive feature about integrase is that there is no known human analogue for this enz...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/15/99 - 02/29/00

DESCRIPTION (Adapted from the application): The goal of this Phase II project is the synthesis and evaluation of indolocarbazole analogues as poisons of human topoisomerase I (Topo I), an enzyme which represents an attractive target for development of antitumor agents. The Phase I study involved synthesis of all four "symmetrical" regioisomers o...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/97 - 09/29/98

The goal of this Phase I project is the synthesis and evaluation of indolequinone and pyrroloiminoquinone alkaloids having structural similarity to the natural products BE 10988 and the makaluvamines, intended as inhibitors of human topoisomerase I and II. Topoisomerase II is the target of man...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/97 - 03/31/98

Robutaflavone, a bioflavonoid isolated from the seed-kernel extracts of Rhus succedanea, exhibited impressive activity against hepatitis B virus (HBV) replication in vitro, with an effective concentration (EC50) of 0.25 mM and a selectivity index (IC50/EC90) of 153. Initial mechanism of action studies showed t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/97 - 02/28/98
PI: Ze-Qi Xu

This proposal is to develop a HIV-1 specific nonnucleoside RT inhibitor. This compound has been shown to have EC50 values ranging from 0.4-1.7 microM against both laboratory and clinical HIV- isolates in the in vitro XTT assay. It is also active against HIV isolates with a mutatio...

Load More